SAN DIEGO, Feb. 15, 2020
/PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel,
LLP, is investigating potential claims against Adverum
Biotechnologies, Inc. ("Adverum " or the
"Company" (NASDAQ: ADVM) on behalf of investors.
The investigation seeks to determine whether certain statements
regarding the results of a clinical drug study of ADVM-022 were
false and misleading when made. ADVM-022 was intended to
treat wet age-related macular degeneration ("wet AMD").
On September 12, 2019, Adverum
issued a press release that disclosed that patients taking the drug
in the study suffered significant deterioration in their
sight. Following this news, the price of Adverum's common
stock dropped from $12.00 to
$5.96 in one day, a decrease of more
than 50%.
If you lost money, realized or unrealized, on your
Adverum investment, and are interested
in learning more about the investigation, please contact lead
analyst Jim Baker
(jimb@johnsonfistel.com) by email or phone at 619-814-4471.
If emailing, please include a phone number.
Additionally, you can [click here to join this
action]. There is no cost or obligation to you.
About Johnson Fistel,
LLP:
Johnson Fistel, LLP is a nationally
recognized shareholder rights law firm with offices in California, New
York, and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
https://www.johnsonfistel.com. Attorney advertising. Past results
do not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com
[click here to join this action]
View original
content:http://www.prnewswire.com/news-releases/adverum-advm-alert-johnson-fistel-launches-investigation-into-adverum-biotechnologies-investors-encouraged-to-contact-firm-301005705.html
SOURCE Johnson Fistel, LLP